ValuEngine Downgrades Aclaris Therapeutics, Inc. (ACRS) to Sell

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Other equities analysts have also recently issued research reports about the company. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Guggenheim reaffirmed a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, June 28th. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, JMP Securities reissued an “outperform” rating and set a $39.00 target price on shares of Aclaris Therapeutics in a report on Friday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $40.00.

Aclaris Therapeutics (NASDAQ ACRS) traded down 1.92% during trading on Tuesday, reaching $26.08. The company’s stock had a trading volume of 218,106 shares. Aclaris Therapeutics has a one year low of $20.15 and a one year high of $33.25. The firm’s market capitalization is $697.27 million. The stock has a 50-day moving average of $26.54 and a 200 day moving average of $27.80.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.12. On average, equities research analysts predict that Aclaris Therapeutics will post ($3.10) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/09/12/valuengine-downgrades-aclaris-therapeutics-inc-acrs-to-sell.html.

In other news, Director Andrew N. Schiff bought 108,601 shares of Aclaris Therapeutics stock in a transaction on Wednesday, August 16th. The stock was acquired at an average price of $23.02 per share, with a total value of $2,499,995.02. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.30% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Nationwide Fund Advisors grew its position in shares of Aclaris Therapeutics by 8.3% in the first quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 510 shares in the last quarter. American International Group Inc. grew its position in shares of Aclaris Therapeutics by 31.3% in the first quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 1,623 shares in the last quarter. UBS Group AG grew its position in shares of Aclaris Therapeutics by 60.4% in the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 1,681 shares in the last quarter. Alps Advisors Inc. grew its position in shares of Aclaris Therapeutics by 7.7% in the second quarter. Alps Advisors Inc. now owns 24,129 shares of the biotechnology company’s stock valued at $654,000 after purchasing an additional 1,718 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in shares of Aclaris Therapeutics by 24.0% in the first quarter. Alliancebernstein L.P. now owns 9,300 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 95.79% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply